Top stories of 2021: Part three A combination of freedoms, lockdowns, surging cases, mask rules, a complicated vaccine rollout, and more has made it an eventful year for GPs.
How vaccine companies are responding to Omicron Scientists are scrambling to test and potentially update their vaccine candidates against the latest COVID variant of concern.
How will Novavax fit into Australia’s COVID-19 vaccine plans? GPs will be involved in the rollout of Novavax if it is approved for use in Australia, the Federal Government has confirmed.
Novavax vaccine could be ready within months Phase 3 clinical trial results confirm it will likely be a ‘very important’ part of Australia’s vaccination program.
Peer review confirms Novavax effective against emerging variant While the vaccine’s efficacy rate is significantly lower against the South African variant than the original strain, there are other factors to consider in a real-world context.
AstraZeneca blood clot link increases importance of Novavax But with clinical trials progressing slowly, uncertainty remains over when Australia will access the 51 million doses of its third vaccine candidate.
Novavax confirms efficacy against emerging coronavirus variants New data on Australia’s third vaccine candidate shows it is highly effective against most COVID-19 variants, which may prove crucial as production bottlenecks force delays among other options.
Novavax candidate may prove best long-term solution for Australia While debate swirls around the first two vaccines set to be used in the rollout, NVX-CoV2373 comes with potential advantages.